Clearside Biomedical(US:CLSD)2021-05-18 02:34Financial Data and Key Metrics Changes - As of March 31, 2021, the company's cash and cash equivalents totaled approximately $26 million, which includes about $14.4 million in net proceeds from a registered direct offering and the use of ATM facilities in January [33] - The quarterly cash burn is primarily due to activities related to obtaining XIPERE approval and the CLS-AX program, with sufficient resources expected to fund operations into the first quarter of 2022 [34] Business Line Data and Key Metrics Changes - The XIPERE New Drug Application (NDA) has been resubmitted to the FDA, which is a significant milestone for the company as it represents the potential for its first commercial product approval [6][9] - The company is also advancing its CLS-AX program, which is currently in a Phase I/II clinical trial, with results from the first cohort expected by the end of June [14][17] Market Data and Key Metrics Changes - Bausch + Lomb has the exclusive license for the commercialization and development of XIPERE in the U.S. and Canada, while Arctic Vision holds the license for Greater China and South Korea [10][12] - Arctic Vision has received approval from the Chinese regulatory authority for their investigational new drug application in uveitic macular edema and plans to begin Phase III clinical trials later this year [12] Company Strategy and Development Direction - The company aims to validate its suprachoroidal injection platform through the potential approval of XIPERE, which could lead to a reliable, non-surgical method for treating retinal diseases [7][9] - The company is also exploring the development of integrin inhibitors for diabetic macular edema and macular degeneration, indicating a diversification of its pipeline [20][75] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the upcoming data from the OASIS trial and the potential U.S. marketing approval for XIPERE later this year [37] - The company remains dedicated to addressing the needs of patients suffering from blinding diseases and is focused on advancing its clinical and preclinical development programs [38] Other Important Information - The company has been active in engaging with the retina physician community and has participated in several key industry events to promote its suprachoroidal drug delivery technology [28][29] - The company anticipates receiving nearly $20 million in non-dilutive funding from milestone payments if XIPERE is approved [35] Q&A Session Summary Question: Clarification on the upcoming Phase I/II study patient enrollment - Management clarified that patients enrolled in the trial had to be treatment-experienced and categorized as VEGF dependent [40] Question: Details on virtual training procedures for physicians - Management discussed a robust training program that includes virtual training using an artificial eye, which has been well-received by physicians [41] Question: Update on pre-approval manufacturing inspections for XIPERE - Management indicated uncertainty regarding the FDA's approach to inspections but noted that they had provided necessary stability data and demonstrated consistency in the manufacturing process [54][55] Question: Durability data expectations for CLS-AX - Management confirmed plans to establish an extension study to follow patients for additional durability data beyond the initial three months [47] Question: Potential immune response benefits of suprachoroidal delivery for gene therapy - Management highlighted the advantages of avoiding surgical risks and suggested that suprachoroidal delivery may lead to a favorable immune response [50][51] Question: Status of the collaboration with Bausch Health regarding XIPERE - Management stated that they will work closely with Bausch Health during the review period to ensure successful launch plans and training [62] Question: Timeline for integrin inhibitors preclinical data disclosure - Management indicated that they hope to share preclinical data on integrin inhibitors before the end of the year [76]